Antiretroviral therapy for decades is the appropriate treatment for infected populations with human immunodeficiency virus (HIV). However, it is associated with complications that affect the organism infected. The combination of antiretroviral therapy and pregnancy degrades iron metabolism. This work aims to evaluate and characterize the impact of the interaction between antiretroviral therapy and different stages of pregnancy in women of Abidjan on all biological indicators of iron status. The conducted investigations were a prospective, cross-sectional, descriptive analytical and case-control study. They concerned 275 women of reproductive age in all trimesters of pregnancy and in consultation to integrated center for Bioclinical research of Abidjan (ICBRA). These women were divided into two groups: 135 pregnant women infected with HIV without antiretroviral therapy as controls and 140 pregnant women infected with HIV receiving antiretroviral therapy. All biological indicators of iron metabolism were determined either by colorimetric or immunoturbidimetric assays through blood samples from each pregnant woman or by calculation. The results of the study showed an extreme degradation in all evaluation of iron metabolism biological indicators assessment in all pregnant women. Analyzes of these biological parameters revealed that pregnant women with HIV and receiving treatment showed a significant alteration of their iron status (92 %) against 62.9 % in control pregnant women. However, latter have indicated a strong immunodepression towards the end of pregnancy with 40 % against 28 % among women on antiretroviral therapy. In addition, control subjects in early pregnancy reported a high rate of inflammatory anaemia associated with iron deficiency (30 % against 0 %) to critical stage (stage C) of HIV infection progression. The interaction between antiretroviral therapy and pregnancy disrupted iron metabolism in pregnant women infected with HIV. This deterioration is greater in infected pregnant women without antiretroviral therapy. The probable reasons for these changes in iron status of pregnant women infected with HIV in Abidjan are pregnancy and antiretroviral medication.
Introduction
Antiretroviral therapy is considered to be appropriate and adapted treatment to population infected with human immunodeficiency virus (HIV). It is based on an arsenal of drugs to multiple properties reducing and neutralizing activity of HIV on the infected organism (WHO. 2006) . In addition, this treatment in infected has shown its effectiveness in the world (Carra and Amin, 2009 ). Thus, antiretroviral therapy has emerged as a way to reduce the infection rate among the population and even acting as a preventive medicine in individuals who may have been exposed to the virus (WHO, 2010) . However, its administration to the infected population is associated with complex complications. Several studies worldwide have shown in all compartments of the body, diseases with antiretroviral therapy (Mintz, 1995; Shet et al., 2009) . These are disturbances of lipid, protein, glucides profiles and even heart disease (Carr et al., 2000) . Worse, this alteration of physiological functions associates the degradation of essential micronutrients metabolism in the body such as iron (Bogden et al., 1990; Rousseau et al., 2000; Ndeezi et al., 2010) . They cover all classes and strata of the population especially women of reproductive age. The most vulnerable among women of reproductive age are pregnant women (McIntyre, 2010; Edmonds et al., 2011; Musoke and Fergusson, 2011) . Women infected with HIV during pregnancy are a high-risk population. Despite, antiretroviral therapy and taking Antianaemic, iron metabolism is greatly affected during pregnancy (Toure et al., 2008; Ouyanga et al., 2010) .
Numerous works in developing countries especially in Africa have reported that antiretroviral therapy would cause anaemia during pregnancy. The impact of anaemia on pregnancy is disastrous for the mother and the fetus. It leads to serious consequences such as the physical integrity of the mother. retarded growth of the fetus in the womb. underweight of newborn at birth and preterm delivery (Antelman et al., 2000; Beaton, 2000; Dreyfuss et al., 2001; Szylda et al., 2006) .
In Côte d'Ivoire, few studies have indicated the influence of antiretroviral therapy in women during pregnancy (Moh et al., 2005) . Similarly there is no information available on the impact of the interaction between antiretroviral therapy and pregnancy across biological indicators of iron metabolism.
In vision of the global strategy of the health sector on HIV/AIDS 2011-2015, envisaged by the United Nations on AIDS (WHO, 2010a; UNAIDS, 2010) , all aspects unexplored and not prospected should be subject to studies. This is the case of antiretroviral therapy and heterogeneity of iron status during pregnancy in Côte d'Ivoire.
This study aims to identify and characterize a possible influence of antiretroviral therapy on biological indicators of iron metabolism assessment and eventual interaction of antiretroviral therapy and pregnancy on these biological parameters. This work has specific objectives to (a) compare depending on trimester, different biological parameters of iron status between the two groups of women; (b) identify and compare the different proportions of main biological parameters according to the women's group and the three trimesters of pregnancy; (c) report and compare the different prevalences of iron metabolism components by trimesters of pregnancy between the two groups of women; (d) reveal the group of infected pregnant women which was most exposed to a possible alteration of iron metabolism; (e) observe the components' evolution of iron status during HIV infection progression in women during pregnancy and (f) indicate the stage of pregnancy during which the interaction of antiretroviral therapy and pregnancy greatly influences the iron status of women.
Materials and Methods

Study population
The investigations were cross-sectional and descriptive study which took place from 21 October 2009 to 21 December 2012 in the Integrated Centre for Bioclinical Research of Abidjan (ICBRA). The study involved 275 women aged from 18 to 45 years with mean age of 28.1 ± 0.7 years during pregnancy. This sample of pregnant women consists of 135 control subjects without antiretroviral treatment at time of selection. These subjects were submitted to antiretroviral therapy after performed blood sampling in context of this study. The second group is composed of 140 HIV infected pregnant women with antiretroviral therapy in the for at least one year and 140 HIV-infected women receiving antiretroviral therapy. These pregnant women came for consultation in Integrated Centre for Bioclinical Research of Abidjan (ICBRA) for prenatal examinations and biological monitoring of their HIV infection for some. Control pregnant women were composed of 50 subjects in the first trimester, 45 in the second trimester and 40 subjects in the last trimester (Fig 1) . Women infected with HIV and on antiretroviral therapy from at least one year, are composed of 40 subjects in the first trimester, 45 subjects in the second trimester and 55 women in the last trimester. In addition, this group of women included 99 % of HIV-1 against 1 % HIV-2. Tritherapy most widely prescribed to pregnant women is characterized by Zidovudine (AZT). Lamivudine (3TC) and Nevirapine (NVP), This set of women from different municipalities and suburbs of Abidjan (Côte d'Ivoire) was selected after informed consent of each woman on the objectives of the investigation.
The 275 selected pregnant women have not presented major complications of hypertension, diabetes, rheumatoid arthritis. In contrast, those with recently reported major health concerns that is transfused, indicating digestive and gynecological diseases were excluded.
The mean age of enrolled women in the study was 25.3 ± 0.5 years and 30.8 ± 0.9 years respectively in control subjects and HIV infected women with antiretroviral treatment. Control subjects included more adolescents (28.5 %) compared to women receiving antiretroviral therapy (2%). These had generally a body mass index (BMI) of 24.6 ± 0.6 kg.m -2 54 % of women had normal weight status against 46 % for abnormal weight status with underweight (14 %) and 32 % overweight. In controls, mean BMI was 23.9 ± 0.4 kg.m -2 52.6 % indicated a normal weight status against 47.4 % for abnormal weight status with underweight (17.8 %) and 29.6 % overweight (Table 1) . The gravidity and parity had mean values of 1.8 ± 0.2 and 1.8 ± 0.2 in women with ART and 3 ± 0.1 and 1.4 ± 0.1 for control subjects. Several study subjects (106 and 84 respectively) had indicated a pregnancy for their obstetric histories. In this same way, respectively 62.2 % and 94 % of women selected had at least one childbirth. In terms of space between births, 67.4 % of control women against 56 % of infected women have observed less than 3 years between pregnancies. Study population also included married, Widows, single and subjects living in concubinage (Table 1) .
Blood samples and assays of biological parameters
For each of the recruited women, a blood sample collected in dry tubes and tubes with 5 ml anticoagulant each were performed fasting bend of the elbow in the morning. Whole blood collected in tubes with anticoagulant (EDTA) achieved the CD4 counts by flow cytometry with Fascalibur® and the blood count by the Sysmex PLC Xt 2000i.
The collected blood in dry tubes was centrifuged at 3000 tours for 5 minutes to obtain the serum. The obtained serum allowed to determine HIV status and biochemical data assessment of iron status.
For HIV serology, the method most used in the care centers. is the use of two successive tests. Once the first test (Determine) is positive, we proceed to discrimination test (Genie II HIV-1/HIV-2) to determine the type of HIV.
The The Student t test for independent samples was used to estimate possible changes of biological indicators of iron status in two groups of HIV infected pregnant women. The obtained values of the biological parameters of iron status were subjected to a factorial analysis of variance (ANOVA) with two factors (the three trimesters of pregnancy and antiretroviral therapy) in order to evaluate one hand, their evolution during different trimesters in infected control pregnant women. And secondly, these tests aimed to reveal an eventual influence of antiretroviral treatment on biological indicators of iron metabolism in two groups of selected pregnant women. These statistics treatments with Statistica Statsoft program Windows version 7.1 were associated NEWMAN-KEULS as multivariate test post hoc to specify the probable groups of women significantly different (Statsoft, 2005) . Different observed proportions of biological indicators of iron status were compared by the G test or log Likelihood ratio test with the software R.2.0.1 Windows version (Ihaka and Gentleman, 1996) . The level of significance was defined for a p value < 0.05.
Ethics
Experimental procedures and protocols used in this study were approved by ethical committee of Health Sciences (Nangui Abrogoua University). These guide lines were in accordance with the internationally accepted principles for laboratory use and care. Approval was also obtained from the Ministry of Higher Education and Scientific Research and the Ministry of Health and Public Hygiene in the Republic of Côte d'Ivoire.
Results
Evolution of iron status biological parameters
The study results in Table 2 showed that all blood counts parameters were abnormal compared with reference values in both groups of women. In the same way, mean corpuscular volume in control women (77.1 ± 0.8 fl) and mean corpuscular hemoglobin concentration in infected pregnant women receiving antiretroviral therapy (31.4 ± 0.2 g/dl) were also abnormal compared to standards. Conversely, other erythrocyte indices indicated normal values compared with references in all infected pregnant women.
For biochemical indicators and CD4, all determined values were normal according to standards except saturation coefficient of transferrin (9.5 ± 0.5 % and 10.9 ± 0.7 % respectively).
Analyses of comparison between the two groups of women generally showed statistically significant differences in mean corpuscular volume (p = 0.04), serum iron (p = 0.04), total iron binding capacity (p = 0. 03), serum ferritin (p = 0.01) and CD4 (p = 0.001). However, other biological parameters of iron status reported no significant difference (p > 0.05) between the two groups of infected pregnant women. Thus, mean corpuscular volume, serum iron and serum ferritin in infected pregnant women on antiretroviral therapy, were more increased than in control women. In contrast, CD4 and total iron binding capacity have been significantly lower in these pregnant women receiving antiretroviral treatment than the control women.
The significant evolution of blood count cells parameters (red blood cells, hemoglobin and hematocrit). Mean corpuscular volume, mean corpuscular hemoglobin, serum iron and saturation coefficient of transferrin in the controls during pregnancy was decreased (Table 3 ). In contrast, serum transferrin, total iron binding capacity, iron stores and CD4 were significantly (p < 0.05) increased during pregnancy in these women compared with infected pregnant women on antiretroviral therapy.
Multiple statistical treatments showed a significant (p < 0.05) interaction between antiretroviral therapy and pregnancy in three haematological parameters (hemoglobin. hematocrit and mean corpuscular volume) and all biochemical indicators of iron metabolism except serum transferrin. Thus, hemoglobin was low in the first trimester of pregnancy in infected women on antiretroviral therapy compared with control women. However, at the beginning and at the end of pregnancy, infected pregnant women reported hematocrit values significantly (p < 0.05) higher compared to control women. In the same vein, mean corpuscular volume in pregnant women on antiretroviral therapy was strongly greatest throughout the three trimesters compared with control women.
For biochemical parameters and CD4 a significant interaction (p < 0.05) between antiretroviral therapy and pregnancy has been observed in study population at the last trimester of pregnancy except for serum transferrin. Thus, infected women on antiretroviral therapy reported values significantly (p < 0.01) greater iron and saturation that women witnesses except at the total capacity of fixation (Table 3) . Another interaction between antiretroviral therapy and all trimesters of pregnancy was reported in regard to the total capacity of attachment and serum ferritin throughout pregnancy. Therefore, iron stores of pregnant women on ART were significantly (p <0.001) was higher compared to control women in all trimesters of pregnancy (Table 3) .
Distributions of proportions of iron status main parameters
In table 4, the two groups of pregnant women infected with HIV have indicated significant differences (p < 0.05) for microcytosis, macrocytosis, proportions of women with low values of transferrin (< 2 g / l) and ferritin (< 15 l / dl). In the same way, the controls have recorded the prevalences of microcytosis, high values of transferrin, of total iron binding capacity and of CD4 greater than infected pregnant women on antiretroviral therapy. However, women on antiretroviral therapy have more indicated macrocytosis (24.3 %), proportion of low values of ferritin (8.6 %) and CD4 (28.6 %) compared with control women.
In addition, the results have showed that 184 women of study population (66.9 %) were anaemic. But no significant difference was observed between the two groups of infected women of study (Table  4) .
Throughout the pregnancy, an interaction between the three trimesters of pregnancy and antiretroviral therapy was significantly observed on proportion of erythrocyte parameters. Thus, high prevalences of anaemia were reported during first and third trimesters of pregnancy in infected women on antiretroviral therapy (90 % and 84 % respectively). In contrast, anaemia was lower in second trimester of pregnancy in these women than the controls (40 % against 51.1 % respectively). Moreover, only infected women on antiretroviral therapy have revealed macrocytosis to last two trimesters of pregnancy (6.7 % and 56 % respectively). Furthermore, these women have presented higher prevalence of hypochromia during the second trimester of pregnancy than the controls (Table 5 ). The results of study have indicated that, control women were concerned by microcytosis throughout the pregnancy and hypochromia to first and third trimester of pregnancy compared with infected women on antiretroviral therapy. According changes of erythrocyte parameters, hypochromic microcytic anemia, normochromic normocytic anaemia, hypochromic normocytic anaemia and normochromic microcytic anaemia were observed in study population. Throughout the pregnancy, hypochromic microcytic anemia and hypochromic normocytic anaemia then normochromic microcytic anaemia to first trimester of pregnancy were more observed in control women compared with women on antiretroviral therapy. In contrast, infected pregnant women on antiretroviral therapy have recorded for the three trimesters, normochromic normocytic anaemia and hypochromic normocytic anaemia then normochromic microcytic anaemia for second and third trimesters of pregnancy (Table 5) .
In table 6, the proportions according to reference values limits of biochemical parameters, an interaction of pregnancy and antiretroviral therapy was revealed. Thus, no woman on antiretroviral therapy has indicated ferritin value below 15 µg/l. In the same way, all control women have reported normal ferritin values between 15 and 150 µg/l during the three trimesters of pregnancy.
Components of iron status and HIV infection progression during pregnancy
Several study women have recorded abnormal iron status (62.9 % and 92 % respectively). The results have shown that women on antiretroviral therapy were more significantly exposed compared with controls (Table 7) . Depending on variation of iron metabolism parameters, components of iron status observed in all women were iron deficiency, iron deficiency anaemia, inflammatory anaemia and inflammatory anaemia associated with iron deficiency. Significant differences were reported between the two groups of HIV infected women. However, inflammatory associated with iron deficiency has not been revealed in infected pregnant women on antiretroviral therapy. In the same way, control women have not been indicated iron deficiency and iron deficiency anaemia. In Table 8 , an interaction of pregnancy and antiretroviral therapy was observed on different components of iron metabolism in study subjects. Thus, control women have reported low prevalence of normal iron status during three trimesters of pregnancy (46 %, 40 % and 22.5 % respectively). For abnormal iron status, iron deficiency was only recorded to second trimester of pregnancy in women on antiretroviral therapy. In addition, these women have reported iron deficiency anaemia to first and third trimesters of pregnancy. Moreover, women on antiretroviral therapy have revealed high prevalences of inflammatory compared with controls. In contrast, control women have indicated throughout high prevalences of inflammatory associated with iron deficiency.
According to evolution of CD4 rates in table 9, no control has presented an immunodepression (CD4 < 200 cells/µl) during first and second trimesters of pregnancy. However, women on antiretroviral therapy have revealed an immunodepression throughout the pregnancy.
For the stages A and B, no study woman has indicated normal iron status to first trimester of pregnancy. In the same way, no control has reported normal iron status for second trimester of pregnancy to these stages of HIV infection. Moreover, all control women with immunodepression have not reported to third trimester of pregnancy normal iron status. Women on antiretroviral therapy with iron deficiency were only in stages B and C to second trimester of pregnancy. Inflammatory anaemia more observed in women on antiretroviral therapy throughout the pregnancy was significant in stages A and B. However, in these women 40 % for first and 28 % for third trimesters of pregnancy with inflammatory were in immunodepression. For control women with inflammatory anaemia associated with iron deficiency, 30 % were in immunodepression (stage C) to first trimester, and 51.1 % in stage B to second trimester of pregnancy. In addition, several controls with inflammatory anaemia associated with iron deficiency (75 %) were in stages A and B (Table 9 ).
Discussion
The specificity of this study is to demonstrate the necessity of using antiretroviral therapy for women during pregnancy with HIV in Côte d'Ivoire. Women with HIV during pregnancy show an alteration of haematological, biochemical and immunological parameters throughout this investigation. This observation is regularly reported by several works in the world (WHO, 2010b) . It is even more pronounced during antiretroviral therapy in pregnant women in developing countries. The main results of this study show that the group of pregnant women infected with HIV without antiretroviral therapy, is more exposed compared with pregnant women on antiretroviral therapy. Indeed, assessment of biological indicators of iron metabolism shows that more than half of HIV infected pregnant women without antiretroviral treatment showed inflammatory anaemia associated with iron deficiency. No iron deficiency anaemia is observed in these subjects. Installation mechanism of anaemia is a dynamic concept. This is carried out using several steps and is characteristic of type of anaemia. In developing countries, main observed types of anaemia are nutritional and infectious origins. Anaemia due to iron deficiency follows three stages (Hercberg et al., 1998) : First, simple depletion of iron reserves without deficiency of erythropoiesis, is characterized by low serum ferritin below standards (below 15 mg/l). Then, depletion with deficiency of erythropoiesis is associated with a decrease in saturation coefficient of transferrin, increase in transferrin and total iron binding capacity, a decrease in serum iron and erythrocyte parameters. The last stage corresponds to iron deficiency anaemia where the hemoglobin level falls below the threshold (Duport et al., 2003) .
The main raison of iron deficiency is the insufficient of bioavailability's iron in the diet of developing countries' population. In addition, iron deficiency is also caused by iron needs during pregnancy. This study reveals that women were concerned by iron deficiency during pregnancy. This result was previously reported in Abidjan with followed women during pregnancy (Bléyéré et al., 2007) . In addition, the previous study has indicated a high prevalence of iron deficiency anaemia in pregnant women. In contrast, our study population shows more inflammatory anaemia. This anaemia is resulted in inflammatory and infectious syndromes. HIV infection causes inflammation in subjects.
This inflammation has an impact on iron metabolism by cytokines, interferons and iron sequestration by macrophages. This whole set disturbs the proper functioning of iron stores (ferritin), transport protein (transferrin) and erythropoietin. In fact, transcription of the erythropoietin gene is facilitated by hypoxia inducible factor 1. Erythropoietin acts through its receptor to exert its proliferative, differentiator and anti-apoptotic effects on erythroid precursors. Gamma interferon, inflammatory cytokines interleukin-1 and tumor necrosis factor -alpha (TNF-a) inhibit the expression of erythropoietin gene, formation of erythroid colony and function (Interferon-gamma) of erythropoietin receptor. This leads to poor erythropoiesis with an insufficient of synthesis in red blood cells. Therefore, blood cell production is weak with an impact on haematological parameters of iron status. In this study, all haematological parameters are modified during pregnancy in subjects. Indeed, a poor unwinding of erythropoiesis causing a defective synthesis of red blood cells, occurs in the body. This insufficiency of blood cell production has an effect on the blood parameters of iron status.
In the event of our research, red blood cells, hematocrit, hemoglobin, mean corpuscular volume (pregnant women without antiretroviral therapy), mean corpuscular hemoglobin and mean corpuscular hemoglobin concentration (pregnant women on antiretroviral therapy) are modified. The Changes in haematological parameters through an inadequate of erythropoiesis can be explained by the disorder of iron metabolism from sequestration by macrophages of iron released through hemolysis. This sequestration of iron causes difficulty of its mobilization from reserves.
This deficit of movement of iron in body leads to (a) a static state or high iron stores (normal or high ferritin); (b) a decrease of plasma transferrin (iron transport protein) due to its hypercatabolism in the inflammatory focus, on the other hand the decrease in its synthesis (iron stores are full); (c) a reactive increase in number of mitoses liable for microcytosis (Tsiakalos et al., 2009) .
These findings are similar to those of our study. Indeed, the mean values of serum ferritin in both groups of pregnant women infected with HIV are normal. Moreover, high prevalence of microcytosis and hypochromia are reported in the group of pregnant women without antiretroviral therapy. In contrast, this study revealed normal concentrations of serum transferrin in all selected women.
Also very few pregnant women infected with HIV of works indicate a decrease in serum transferrin. Inflammatory anaemia may to know two phases of evolution; (a) anaemia is initially normocytic normochromic arégénérative and (b) inflammation persisting, anaemia may be hypochromic and microcytic (Beisel, 1992; Boelaert et al., 1996) . This could explain the high rates of hypochromic microcytic anemia and normochromic normocytic anaemia in selected subjects of study. Furthermore, a high prevalence of macrocytosis is observed only in pregnant women infected with HIV on antiretroviral therapy. This is contrary of all events that occur during a change of iron metabolism in HIV infection.
This macrocytosis could be justified by nonobservance of recommended folic acid during pregnancy. According to work of Remacha et al. (2003) , a significant macrocytosis is observed in Spanish HIV and without antiretroviral therapy, which is against to our findings. Difference in physiological states among subjects of the two studies could explain these opposite results. Moreover, a large proportion of control pregnant women indicate high values of transferrin that leads to inflammatory anaemia associated with iron deficiency in these subjects. This result is similar to that reported by Walsh et al. (2010) in South African with 23.9 % against 24.9 % in ours with high concentrations of transferrin.
Our study reveals that in antiretroviral therapy in women during pregnancy with HIV infection, altered metabolic pathways of iron is observed. Similar results were reported by Kurz et al. (2010) in HIV infected pregnant women with high antiretroviral therapy in Latin America and caraïbes, with a prevalence of anaemia of 12.2 % against 62.2 % (Pregnant Women without antiretroviral therapy) and 71.4 % (pregnant women on antiretroviral therapy).
In the event of our investigation, prevalence of anemia is higher than that indicated in the Latin American and caraïbean. The interaction between antiretroviral therapy and pregnancy on biological indicators of iron metabolism assessment has an impact on haematological parameters, iron, transferrin, total iron binding capacity and saturation coefficient of transferrin in first trimester and third trimester. However, this interaction is more active throughout pregnancy (in all three trimesters) on iron stores (ferritin), inflammatory anaemia and inflammatory anaemia associated with iron deficiency. These results are contrary to those reported by Bléyéré et al. (2007) in non HIV infected pregnant women in Abidjan. For these authors, iron metabolism is altered in the last trimester of pregnancy. The observed type of anaemia is of nutritional origin. This could be explained by infectious and inflammatory syndrome caused by HIV infection in pregnant women.
In addition, HIV infected pregnant women on antiretroviral therapy indicate inflammatory anaemia most important in stage A of HIV infection during the last two trimesters of pregnancy. In contrast, infected pregnant women and devoid of antiretroviral therapy reveal inflammatory anaemia with iron deficiency in early pregnancy at stage C of HIV infection.
The evolution of CD4 count in pregnant women during antiretroviral therapy is increasing (Batterham et al., 2001 ). This observation is similar to that reported in our research on pregnant women with antiretroviral therapy. However, it is contrary to infected pregnant women without antiretroviral treatment. This is revealed in control pregnant women of our investigation. Loko et al. (2005) and Smith et al. (2005) also indicated low rates of pregnant women during their work. In addition, altered iron status in infected pregnant women in their entirety, observed during our work has also been noticed by Weinberg et al. (2001) . Conversely, Semba et al. (2001) revealed that the status is not based on the progression of HIV infection in pregnant women. Antiretroviral treatment would reduce deficiency and overload of some micronutrients such as selenium, zinc, copper and even iron. The work of Rousseau et al. (2000) over four years of antiretroviral therapy in subjects infected with HIV showed that a decrease of iron deficiency (< 6 µmol/l) from 19 % to 13 %, selenium (< 60 mg/l), 77 % to 10 % and copper overload (> 140 mg/dl) from 9 % to 43 % among 44 HIV infected subjects on high antiretroviral therapy.
Antiretroviral therapy depresses prevalence of opportunistic gastrointestinal diseases and severe gastroenteritis. These pathologies affect the absorption of micronutrients. However, several medications against HIV (NRTI3) can inhibit the replication of mitochondrial DNA and cause vomiting and diarrhea that may reduce absorption or increase losses of several micronutrients. This could also explain the degradation of iron metabolism in women in our study. Nutrition and pharmacology of antiretrovirals are actually related (Baum et al., 1995; Drain et al., 2007; Raiten, 2011) as this study so well indicates.
Conclusion
Antiretroviral therapy and pregnancy disrupted various biological indicators of iron metabolism assessment in all pregnant women with HIV. Infected pregnant women with antiretroviral therapy are more changes of iron status parameters compared with those who are not on this medication. All components of the iron metabolic pathways such as iron deficiency, iron deficiency anaemia, inflammatory anaemia and inflammatory anaemia associated with iron deficiency, are reported in this work.
The interaction between antiretroviral therapy and pregnancy on biological indicators of iron metabolism has an impact on haematological parameters and most of biochemical parameters in first trimester and third trimester. In addition, this interaction is more active throughout pregnancy (all three trimesters) of iron stores (ferritin), inflammatory anaemia and inflammatory anaemia with iron deficiency. Pregnant women on antiretroviral therapy (ARVT) indicate high rates of inflammatory anaemia at last trimester of pregnancy in stage C (≥ 500 cells/µl) of the HIV infection.
However, control women have a high prevalence of inflammatory anaemia with iron deficiency in early pregnancy stage C (≤ 200 cells/µl) of HIV infection.
